Abstract
Objective: The focus of this research has been to improve efficacy, decrease tolerance and increase the irinotecan pharmacokinetic profile.
 Methods: Proniosomesformulated with various surfactants, cholesterol and dicetyl phosphate using the slurry method. A slurry process was used to prepare proniosomes with maltodextrin as the carrier by using surfactants span 20, span 60, tween 20 and tween 80.
 Results: The preparations were characterized in terms of shape and specific surface area, entrapment efficacy, in vitro release studies, in vivo tissue diffusion and stability testing. The proniosome surface was found to be smoother in nature showing thin and compact layer with skim milk powder. For formulation 2 (73.94±2.8%), the maximum entrapment efficacy was found.
 Conclusion: The formulation 3 obtained the desired maximum release profile within 24 hours (98.06%). The in vivo tissue distribution studies for the proniosomes reveal that the drug was preferentially targeted to liver followed by the alveolus and lymphatic system.Stability studies have indicated that the most acceptable condition for storage of the formulation 2 was 4o C. Proniosomes provide an acceptable method to the carrier for targeted therapy. These can be held at specific sites and can release the drug for a prolonged period of time.
Highlights
The principle of drug delivery to a given spot for the control of specific disease, thereby reducing the side effects of the drug and increasing their therapeutic index is considered as an obstacle [1,2]
The in vivo tissue distribution studies for the proniosomes reveal that the drug was
*Corresponding author: E-mail: pgoudanavar01@gmail.com; Goudanavar; JPRI, 33(41A): 230-238, 2021; Article no.JPRI.72209 preferentially targeted to liver followed by the alveolus and lymphatic system.Stability studies have indicated that the most acceptable condition for storage of the formulation 2 was 4o C
Summary
The principle of drug delivery to a given spot for the control of specific disease, thereby reducing the side effects of the drug and increasing their therapeutic index is considered as an obstacle [1,2]. The principle of a drug carrier with accuracy has always impressed researchers for generations and limited success has been achieved in this regard over the last decades. This strategy includes the use of vesicular dosage forms which can provide selective toxicity in conjunction with an optimal drug content [3]. Proniosomes overcome all the disadvantages of niosomes and provide the potential for targeted drug delivery with a flexible vesicular delivery model. They include dry surfactant-coated carrier compositions which are hydrated to obtain a suspension of niosomes before their use. The enhanced convenience for transport, delivery, storage and dosing makes proniosomes a promising industrial commodity [8,9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
